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Used contractions: 
ALDH – aldehyde dehydrogenase 
Bcl-2 - B-cell lymphoma 2 
BTM – basal transcription machinery 
CBP -  CREB-binding protein 
CDCA3 - Cell division associated protein-3 
EGFR – epidermal growth factor receptor 
EMT - epithelial-mesenchymal transition 
EOC - Epithelial ovarian cancer 
ER -  estrogen receptor 
FADD - Fas-associated protein with death domain 
GTF - general transcription factor 
H3K27me3 – trimethylation to the lysine 27 on the histone H3 
H3K4me3 – trimethylation to the lysine 4 on the histone H3 
HAT – histone acetyltransferase 
HOX - Homeotic complex  
Hs578T – Homo Sapiens 578T 
ICAM-1 – intercellular adhesion molecule 1 
IGF – insulin-like growth factor 
IGFBP - insulin-like growth factor binding protein 
ISL1 - Insulin gene enhancer protein 
MBIC - muscle invasive bladder cancer 
MCF-7 - Michigan Cancer Foundation-7 
MEIS – myeloid ecotropic integration site 
NEP – neural endopeptidase 
NF-kB - nuclear factor kappa-light-chain-enhancer of activated B cells 
NMBIC - non-muscle invasive bladder cancer 
NSLMC – non-small-cell lung carcinoma 
OSE - ovarian surface epithelium 
PAX8 - paired box gene 8 
PBC - Pre-cell B leukaemia transcription factor 
PIC – preinitiation complex 
RAR - retinoic acid receptor 
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RARE - retinoic acid responsive element 
RBX – RING-box 
RKO – colorectal carcinoma 
SCF – Skp, Cullin, F-box 
SLMC - small-cell lung carcinoma 
SNP – single nucleotide polymorphism 
SRC-3 - steroid receptor coactivator-3  
TAD – topologically associating domain 
TALE - three amino acid loop extension 
TBP – TATA-binding protein 
TF – transcription factor 
TNF – tumor necrosis factor 
TNFR - tumor necrosis factor receptor 
VLA – very late antigen 
Wnt – Wingless/Integrated 
Wt1 - Wilms tumor protein 
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1. Introduction 
Genes are stretches of DNA containing specific instructions to form proteins. Proteins are 
synthesized according to this DNA code every day during embryogenesis as well as in adult 
organism. To develop a functional organism from one single cell and to maintain its 
homeostasis when it is mature, very precise regulation is needed. Every cell contains a copy 
of the same DNA sequence or, in other words, all the possible genes for that particular 
organism. But only a certain part of them is used for protein synthesis and even this protein 
coding part is regulated by different stimuli such as hormones, for example. 
Hormones may act through nuclear or cell membrane receptors, depending on their 
solubility. Hormone binding to the receptor leads to activation of certain transcription factors 
needed for the initiation of a process known as transcription or production of mRNA from 
the DNA. Different transcription factors have different targets that are activated or inactivated 
by them, also they may be activated differently. In this thesis I will discuss the role of HOX-
family transcription factors in different cancer types. 
1.1. Protein synthesis and transcription 
To create an mRNA copy of a gene coding a certain protein, a particular region of the DNA 
is used as a template to produce a complementary mRNA. Process of mRNA synthesis is 
done by RNA-polymerase that binds to a promoter region of genes. To direct the binding of 
the RNA-polymerase to a particular promoter region a group of different proteins is needed. 
There are many supportive proteins and transcription factors that belong to this group. Thus, 
initiation of transcription is the process where transcription factors significance is highlighted. 
Therefore, this process should be described more in detail to uncover the role of 
transcription factors. Since the thesis is focused on human HOX-proteins we will only 
describe eukaryotic transcription. 
Basal transcription machinery (BTM) contains fundamental elements needed for 
transcription in general which can be affected or directed by other transcription factors for 
more specificity, for example by HOX-proteins. 
Main components of the BTM - 1) RNA-polymerase (II), 2) transcription factor (TF) 
complexes - TFIIB, TFIID, TFIIE, TFIIF, TFIIH and TFIIA, 3) Mediator-complex of proteins.  
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Figure 1. Schematic summary of a Pol II transcription preinitiation complex (PIC). Core promoter 
elements are depicted at positions –35, –25, +1 (start site of transcription) and +30. PIC assembly 
is nucleated by binding of the TBP subunit of TFIID to the TATA box, followed by stepwise binding 
of the general transcription factors, TFIIB, Pol II/TFIIF, TFIIE and TFIIH. (Figure and text from 
Krishnamurthy-Hampsey 2008) 
To start describing the initiation of transcription, the structure of the gene is also to be 
determined. Gene consists of the following main regions: enhancer region, promoter region, 
and coding region. Promoter region includes a very important consensus motif called TATA-
box. TATA indicates here a repeating pattern of thymine and adenine nucleotides. TFIID 
starts the formation of the preinitiation complex (PIC) by specifically binding to the TATA-
box with help of its TBP (TATA-binding protein) subunit. This binding promotes structural 
changes strongly bending the DNA. The enhancer region may be located after the promoter 
region in the direction to 5' end of the DNA or in the 3' direction. The role of the enhancer is 
to bind transcription factors, for example, HOX-proteins. 
TFIIB is responsible for the next step of PIC formation. This transcription complex is able to 
bind TBP of the TFIID and it also binds DNA with its helix-turn-helix motif (Reese 2003). 
Apart from TFIIB transcription complex TFIIA also interacts with TBP thus stabilizing the 
PIC.  
TFIIH has helicase and ATP-hydrolase activity, so it plays a role in DNA unwinding that is 
critical for transcription initiation. It has also kinase activity to phosphorylate the CTD domain 
of the RNA-polymerase. CTD phosphorylation is needed for initiation and processivity of the 
RNA polymerization activity of the RNA polymerase. 
TFIIE ensures the binding of TFIIH to the PIC (Okamoto et al 1998) and possibly has other 
roles. TFIIF does not play a role in the transcription initiation as such, but it was observed to 
stabilize TFIIB after transcription initiation (Cabart et al 2011).  
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The binding of inactive RNA-polymerase to the complex happens via the TBP domain of 
TFIID.  
The next level of the transcription is a big protein complex called Mediator-complex. It has 
many functions one which is signal transduction from the activators or repressors bound to 
enhancer region. For example, Med19 a member of the Mediator-complex was found to bind 
Hox-protein in Drosophila melanogaster and thereby access RNA polymerase II machinery 
(Boube et al 2014). Mediators or cofactors are essential for relaying the stimulus from 
specific transcription factors (like, for example, HOX-protein) to the general transcription 
machinery (Figure 2). 
 
Figure 2. The Mediator complex, composed of four modules – tail, middle, head and CDK8 –, binds 
physically to PolII, principally through its head module. Hox transcription factors (HD in blue, its three 
α-helices indicated as cylinders) bind to regulatory DNA sequences distant from the transcription 
start site (grey arrow), together with unknown numbers of other TFs (here, Hox co-factors Exd and 
Hth plus cell-specific factors TF1 and TF2). We propose that the DNA-bound Hox homeodomain 
serves to recruit MED directly through Med19 HIM (green hook). This Hox-MED association then 
permits the general PolII transcription machinery (PolII+GTF) to be recruited to the Hox target 
promoter. Text and figure from Boube et al 2014. 
2. HOX-protein family and their structure 
In human, HOX-proteins can be divided into 13 paralog groups that can be further divided 
into 4 groups from A to D based on their genomic location. HOX paralogs within each cluster 
are located in a single locus in the 3’ to 5’ direction starting from the 1st to the 13th paralog 
respectively. The closer the gene is to the 3’ end of the HOX locus the more anterior part of 
the body is mapped by respective HOX protein during the embryogenesis. Therefore, HOX 
proteins can also be divided into 3 following groups: anterior (paralogues 1-4), central 
(paralogues 5-8), posterior (paralogues 9-13).  
HOX proteins contain two main parts: a hexapeptide motif and a homeodomain. The latter 
is closer to the N-terminus and is responsible for DNA binding. It contains three helices with 
loops between them (helix-loop-helix motif). The first two helices lie in the minor groove of 
the DNA while the third helix makes specific contacts with base pairs of the major groove. 
However, sequences recognized by the third helix are just 4-6 base pairs long, therefore, 
there is a big possibility for such sequences to be repeated several times in different parts 
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of DNA and these sequences are not enough to create specificity for such transcription 
factors as HOX proteins. So it is logical that there must be a way to increase the specificity. 
Pre-B cell leukaemia transcription factor (PBC) play an important role in conveying 
specificity to HOX DNA-binding. 
PBC proteins also contain a homeodomain but their homeodomains belong to three amino 
acid loop extension (TALE) class. Homeodomains of HOX and PBC proteins both contain 
the homeobox sequence found in different eukaryotes. Both HOX and TALE domains 
contain a helix-turn-helix motif but in TALE proteins there are three extra amino acids 
between two first helices. The homeodomain of HOX proteins contains 60 amino acids and 
the homeodomain of PBC proteins contains 63 amino acids. HOX and PBC proteins form 
heterodimers through the hexapeptide motif of HOX proteins (will be discussed later). The 
consensus sequence in the enhancer region recognized by HOX/PBC heterodimer is 5'-
TGATTNAT-3', where TGAT (1-4 base pairs) is recognized by PBC homeodomain and 
TNAT (5-8 base pairs) by HOX homeodomain. The 6th base (depicted as N) varies in 
different HOX proteins and determines their binding specificity. However, this specificity was 
observed for single HOX proteins, whereas HOX-PBC heterodimers got more flexibility at 
position 6. 
Hexapeptide has the following consensus sequence: hydrophobic residue-Y/F-P-W-M-K/R 
(Piper et al 1999). In contrast, another study reported great variation in the hexapeptide 
sequence in HOX proteins and suggested that only the tryptophan is common to all the 
different variants (LaRonde-LeBlanc-Wolberger 2003). Hexapeptide motif forms a 310 helix 
the function of which is to insert the very conserved tryptophan residue in the hexapeptide-
binding pocket of the PBC proteins (Piper et al 1999). 310 helix is a subtype of α-helix, but 
310 helices are usually short and they are triangular in a cross-section. 
3. Function of HOX proteins. 
3.1. As transcription factors in embryogenesis. 
The main role of HOX proteins is to direct the transcription during embryogenesis. It is a 
complicated process and its mechanism still contains many unknown details. However, 
there are many different hypotheses about different parts of this regulation that provide 
together an interesting picture of the patterning along the anterior-posterior axis during 
embryonic development. 
Vertebrates have an exceptional organization of HOX-genes in the genome comparing to 
other species. In vertebrates, HOX genes are densely clustered in 4 different groups on four 
different chromosomes. During the evolution, the organization of HOX-genes developed 
from dispersed to clustered in the vertebrates. These four clusters are A, B, C and D that 
can all be divided into 13 paralogs. Clusters contain different amounts of paralogs, often 
missing a few. But in the vertebrates, it is never more than 13 paralogs per each cluster. 
Moreover, the direction of gene transcription is the same for each paralog inside the cluster 
in vertebrates. 
The expression of HOX-proteins starts in the posterior-to-anterior direction of the epiblast 
and is collinear with the organization of HOX-clusters. HOX-genes that are closer to 3' end 
of the DNA are expressed more anteriorly and vice versa. This is called spatial collinearity 
and it is directly connected to the second important feature of HOX-patterning – temporal 
collinearity. Temporal colinearity means that more anterior parts along the embryonic axis 
are developed earlier than more posterior ones.   
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The precise mechanism of the HOX-gene establishment during embryonic development is 
unknown, but there are several interesting hypotheses. Two first hypotheses are based on 
the different sensitivity of enhancers of HOX to the inducer (the possible inducer will be 
discussed later). It was hypothesized that more anterior HOX-genes are more sensitive to 
the inducer and thus the gradient of the spreading inducer would determine the individual 
HOX-expression for different regions of embryonic cells. In the first hypothesis, the constant 
spreading of the inducer is required, whereas only a short-time exposure is required 
according to the second hypothesis.  
The most preferred model, however, is based on histones instead of enhancer sensitivity. 
The three-step model is based on the fact that the inducer is spread starting from the more 
posterior part. So it affects more posterior cells earlier, in which it is believed to affect histone 
binding at the HOX-cluster region. Depending on its duration of effect it manages to "open" 
the HOX-cluster to a different extent in different parts of the epiblast. So, in more posterior 
parts, the "opening" would progress starting from more anterior cluster to more posterior, 
whereas in more anterior parts of the epiblast only more anterior clusters would be ready for 
the transcription. After exposure to the inducer, each region of cells would acquire an 
individual HOX-expression program in which only more posterior parts of the epiblast would 
express the posterior clusters (Gaunt-Strachan 1996). 
3.1.1. Genetic regulation of HOXA-cluster as an example 
Although HOX genes are master regulators, they, like other genes, also need to be 
expressed with the help of certain activators. Still, the precise regulation of the initiation of 
HOX-genes' transcription is not entirely clear. 
The putative HOX inducer in the posterior part of the epiblast is Wnt3 that was found to be 
expressed in the proximo-posterior epiblast before the gastrulation (Rivera et al 2005).  
To explain the proposed effect of the Wnt-signal on expression some terminology has to be 
revised. H3K4me3 is a three-methylated modification of histone H3 that is known as an 
activating or a state of the histone in which it is not tightly bound to the DNA thereby allowing 
transcription. On the opposite, H3K27me3, another three-methylated modification of the 
histone H3, is associated with the downregulation of gene transcription or, in other words, a 
state where histone is bound to the DNA.  
The correlation between the time of Wnt-induction and the amount of the two above-listed 
types of histones was studied in epiblast tissues. It was observed that the longer the time of 
Wnt-induction the more H3K4me3 and less H3K27me3 modifications we seen across the 
HOXA cluster. So the exposure to Wnt opens the DNA in the region of the HOXA cluster 
making it accessible for further transcription.  
Like other genes, HOXA-cluster requires  enhancer regions to transmit the signal from the 
inducer molecule. Although in the transcription model regulatory region is usually located 
next to the gene  in the 3' side direction, it is not necessarily structured this way. Regulatory 
regions of a given gene may be placed relatively far, moreover, the same "regulatory cluster" 
may be responsible for more than one gene as in the case with HOXA-cluster. Areas of the 
chromatin where the self-interaction is most abundant are called topologically associating 
domains (TAD). So these are areas of the chromatin where the interactions between the 
particular gene and its regulatory elements occur.  
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The big area called 3'subTAD and also a part of 5'TAD are parts of chromatin that contain 
the highest amount of interactions with the HOXA cluster and its inducer. HOXA cluster lies 
between two TADs: 3'TAD and 5'TAD, where region 3'subTAD is a part of 3'TAD that also 
contains the HOXA cluster itself. Most genes of the HOXA cluster have interactions with 
3'subTAD, whereas the HOXA13 is the only one to interact with the 5'TAD.  
3.1.2. Cis-regulation of HOXA-genes 
In this subchapter, the structure of the 3'subTAD will be discussed to show possible 
enhancers and other regulatory parts that are observed to be involved in the regulation of 
HOX-genes’ transcription.  
Wnt-pathway is the signal transduction leading to the stabilization of the β-catenin that is 
transported to the nucleus and acts as transcription factor. In the case of the HOXA-cluster, 
binding sites of the β-catenin are hypothesized to be possible enhancer regions required for 
the transcription initiation.  
Elements of the 3'subTAD that are observed to regulate expression of the early HOXA genes 
are called HOXA developmental early side (Ades). There are six Ades proteins. Ades1 is 
involved in the expression of HOXA1 member of HOXA-cluster, so the initial signal from the 
Wnt3 activates the transcription of the HOXA1 gene through Ades1 regulatory element. 
Ades2-Ades6 were observed to interact with 3' and middle HOXA genes. β-catenin binding 
sites overlap with all the six Ades regions (Neijts et al 2016). 
The first enhancers becoming active are Ades1 and Ades2 that become acetylated after the 
exposure to Wnt3. This leads to the initial expression of the HOXA1 in the posterior-anterior 
gradient direction of the spreading Wnt3 along the epiblast. It was also noticed that Ades 
regions 3-6 may already interact with β-catenin in an uninduced epiblast, whereas Ades1 
and Ades2 are opened only upon exposure to Wnt3. When all the enhancers are acetylated 
together with the gradual HOXA cluster opening the expression continues from HOXA1 
towards 5' neighbors.  
In the case where Ades1-6 enhancer region was deleted only the response of HOXA1-
HOXA5 was decreased, while 5' neighbors HOXA7 and HOXA9 were not affected. Wnt 
signaling through Ades enhancers is important for the transcription initiation of more anterior 
HOXA genes in the very beginning of the gastrulation. 
The expression of the HOXA-cluster middle part was observed to require Cdx2 that is 
needed for opening the DNA region of middle HOXA genes. Interestingly the expression of 
Cdx2 is regulated by the Wnt3 signal, such that it gets expressed in the epiblast only after  
exposure to Wnt3 (Neijts et al 2017). 
The last member of the cluster to be expressed is HOXA13, but its expression is probably 
regulated by other enhancers located in the 5'TAD. HOXA13 acts as a transcription factor 
and stops the axial elongation, and regulates limb development. 
 
 
4.  HOX - proteins and carcinogenesis 
Due to the fundamental role of HOX-family proteins in embryogenesis, alterations of HOX 
expression are known to be connected with different cancer types. Furthermore, not only 
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the up- or downregulation may play a crucial role, but also the type of tissue affects the final 
result of HOX-protein expression. In this chapter different types of cancer will be discussed 
with the focus on the role of HOX-proteins in carcinogenesis. 
4.1. Prostate cancer 
Prostate cancer is the second most common cause of death amongst males in the world, 
therefore the understanding of the origin of this disease is of high importance (Zhao et al 
2016).  There are various correlations that can be observed for HOX-proteins expression in 
prostate cancer cases, but the interpretation is uniformly nuanced. 
4.1.1. HOXC8 and HOXB13 as a source of androgen insensitivity 
The expression of HOXC8 correlates with the Gleason grades of prostate tumors. The more 
aggressive the cancer, the higher the HOXC8 expression (Waltregny et al 2002). In benign 
cells, HOXC8 proteins are almost absent or totally absent, however, in prostate cancer cells 
its production increases significantly (Waltregny et al 2002). HOXC8 is a transcription factor 
of the HOXC subfamily that is suggested to inhibit CBP (or CREBBP) histone 
acetyltransferase activity (Shen-Krishnan et al 2001), although other sources suggest that it 
is rather a nuclear receptor coactivator (SRC-3) protein than CBP the activity of which is 
inhibited by HOXC8 (Axlund et al 2010). CBP and p300 are coactivators needed for 
androgen receptor to function as a transcription factor inside the nucleus of the cell, these 
proteins contain the histone acetyltransferase domain (HAT) that is needed to perform 
acetylation of lysine residues in histone. The acetylation of the lysine residues leads to DNA 
and histone unbinding by neutralizing positive charges of lysine residues (Liu et al 2008).  
As for SRC-3, it is also the transcriptional coactivator with the HAT activity needed for DNA 
and histones unbinding. In the presence of overexpressed HOXC8 prostate cancer cells 
become resistant to androgen stimulation (Miller et al 2003). CBP HAT activity inhibition is 
also a possible outcome of HOXB13 protein action (Kim et al 2010). 
The fact that the androgen activated pathway is inhibited in prostate cancer cells seems to 
be counterintuitive  because androgen mediates growth-stimulating signals. But there is an 
assumption that it may be explained by the need for cancer cells to be resistant to androgen 
action because the latter is able to inhibit HOXC8 expression. At early stages, cancer cells 
may get prepared for the androgen action by preliminary inhibition of its receptor expression 
(Miller et al 2003). 
4.1.2. HOXC6 as a possible inhibitor of apoptotic pathways; activator of proliferation 
Another possible mechanism of HOX-proteins’ action is connected to the expression of 
neutral endopeptidase (NEP) and insulin-like growth factor binding protein (IGFBP-3). The 
actual mechanism is not yet known so this information is based on the expression correlation 
between HOXC6 and the two above-listed proteins. It was observed that the expression of 
HOXC6 is significantly increased in malignant cells when compared with benign cells. 
Together with the upregulation of HOXC6 downregulation of NEP and IGFBP-3 was 
observed. Both of these proteins relate to the group of proapoptotic genes, but these 
proteins use different mechanisms of switching on the controlled cell death.  
NEP causes the proteolysis of neuropeptides as endothelin-1 and bombesin (Sumitomo et 
al 2001). Endothelin-1 and bombesin proteins are small peptides needed for activation of 
insulin-like growth factor receptors-1 (IGF-1) and the Akt kinase thus increasing growth and 
proliferation of cells. Besides this mechanism, NEP also acts as an inhibitor of c-SRC kinase 
the active state of which is required for cell proliferation. c-SRC is usually activated with 
bombesin and endothelin-1. Also, NEP is able to inhibit protein kinase C degradation thus 
inducing the apoptosis in the presence of phorbol-esters (Sumitomo et al 2000). It is 
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important to mention that all above-listed  mechanisms can take place only in androgen-
sensitive prostate cancer cells because the expression of NEP is regulated by androgen 
receptor that is present in required amount only in androgen-sensitive cells (Shen et al 
2000). 
IGFBP-3  is similarly involved in IGF-1 signaling but as an antagonist of IGF-1 receptor 
preventing activation of the metabolic pathway by IGF-1 and inhibiting cell proliferation 
(Thelen et al 2004). Furthermore, the action of IGFBP-3 is also connected with transforming 
growth factor (TGF-β) signaling; TGF-β inhibits growth and activates apoptosis through 
TGF-β receptors. Although it is not clear whether there is any direct interaction between the 
TGF-β receptor or not it is known that in the presence of IGFBP-3 the sensitivity of TGF-β 
growth inhibitory signaling gets increased. (Fanayan et al 2000). Therefore, it can be 
concluded that cell proliferation is activated in androgen-insensitive prostate cancer cells 
with elevated HOXC6 expression. Additionally, apoptotic pathways are inhibited by possible 
downregulation of NEP and IGFBP-3. 
4.1.3. HOXB3 may possibly transactivate expression of CDCA3 
Cell division associated protein-3 (CDCA3) belongs to the F-box-like proteins group, it 
means that it is a part of SCF complex belonging to E3 ligases the function of which is 
ubiquitination. SCF complexes consist of the following parts: F-box protein, Skp1, cullin, and 
RBX1. F-box part of the complex is the specificity determining part; Skp1 and cullin are 
structural parts of the complex linking the F-box protein and RBX-1 protein the second of 
which serves the enzymatic activity transferring the ubiquitin to lysine residues of the target 
protein (Nakayama et al 2005). 
The role of the whole SCF complex is the recruitment of proteins to proteasomes for 
proteolysis. In the case of CDCA3 at the position of F-box protein in the complex, the target 
protein for degradation is Wee1 kinase. Wee1 kinase functions as an inhibitor of cyclin-
dependent kinase 1 (cdk1) that activates cell proliferation when it is phosphorylated 
(Nakayama et al 2005). 
It was suggested that HOXB3 binds to the CDCA3 promoter region thus activating the 
expression of the CDCA3. In case of elevated expression of HOXB3, the following 
upregulation of CDCA3 leads to increased cell proliferation rate (Chen et al 2013). 
4.1.4. Downregulation of HOX-co-activators Pbx1 and Meis1, Meis2 
Pbx and Meis proteins are known to interact with HOX proteins. Pbx proteins contain a TALE 
motif that is able to bind the hexapeptide motif of HOX proteins (Piper et al 1999). There is 
also an α-helix (α4, HCM) domain that binds to the homeobox pattern of DNA (Piper et al 
1999). Furthermore, PBC-A and -B domains in Pbx proteins bind to Meis proteins (Rhyoo et 
al 1999). As for Meis proteins they contain HM1 and HM2 domains required to interact with 
Pbx proteins (Rhyoo et al 1999, Burglin 1997, Burglin 1998). 
HOX, Meis, and Pbx form a protein complex. The role of this complex is not yet understood 
and it is not clear whether these interactions affect the specificity or activity of HOX-proteins. 
But there is a piece of evidence suggesting that downregulation of Pbx1, Meis1, and Meis2 
during the progression of prostate oncogenesis may be connected with alterations in HOX-
protein activity (Chen et al 2012). Also, it has been reported that this interaction does affect 
the target genes of HOX-proteins. A particular mutation in the Meis interaction domain of 
HOXB13 protein is connected with prostate cancer (Ewing et al 2012). This data suggests 
that dysregulation of Meis-HOX interaction may lead to the development of prostate cancer. 
Also, Meis1 and Meis2 and Pbx1 proteins may function as possible tumor suppressors 
targets for prostate cancer diagnosis or therapy (Chen et al 2012). 
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4.1.5. SNP inside the RFX6 gene a possible predisposition to increased HOXB13 
activity 
Single nucleotide polymorphism (SNP) is a single nucleotide variation in the genome of 
different individuals. SNPs are mostly found outside the coding regions of genes. Most SNPs 
do not influence the protein sequence, but some do. rs339331 is one of the many SNPs 
within an intron of RFX6 gene. rs339331 has either C or T nucleotide at position 500 of the 
RFX6 gene. The gene itself is located in chromosome 6 at locus 6q22. 
It was observed that the presence of rs339331 T-variant increases the binding of HOXB13 
proteins thus increasing expression of the RFX6 gene (Huang et al 2014). 
RFX6 gene codes the protein that functions as a transcription factor that is known to be 
required, for example, for pancreatic islet cell development (Soyer et al 2014). But there is 
also evidence that RFX6 upregulation is associated with prostate cancer progression 
(Huang et al 2014). Therefore, it was suggested that rs339331 T-variant may function as a 
genetic predisposition to prostate cancer and also a possible target for diagnostic 
sequencing. 
4.2. Breast cancer 
4.2.1. HOXA5 and apoptosis 
The activation of HOXA5 expression was observed to be directly associated with apoptosis 
in breast cancer cells. As for MCF7 cells with non-mutated p53 gene HOXA5 activated its 
transcription and subsequent apoptosis cascade (Gupta 2002). But interestingly, p53 was 
shown not to be the absolute requirement for HOXA5 to activate the apoptosis in Hs578T 
cells.  The DNA of this cell line contains a mutated p53 gene, the mutation affects the binding 
domain of this gene, and therefore HOXA5 is not able to upregulate this gene (Chen et al 
2004). 
However, the mechanism, in this case, is not well-understood. It is almost definite that 
HOXA5 activation leads to increased caspase 2 and caspase 8 activity, but the exact way 
how it happens is not clear, although there are several worthy deductive hypotheses (Chen 
et al 2004). HOXA5 is not able to directly upregulate caspase 2 and caspase 8 proteins, 
also apoptotic pathway cannot be activated through p53 in Hs578T cells.  The first 
hypothesis proposes an idea of some unknown molecule functioning as proteinase for 
procaspase 2 and 8 cleavage whose activation is regulated by HOXA5. The next hypothesis 
is connected to another pathway that starts with the tumor necrosis factor receptor (TNFR) 
family. These receptors relay a signal through different TNFR-associated proteins with death 
domains (for example, FADD). So, it is proposed that some adaptor molecules as FADD 
might exist and be activated directly or indirectly by HOXA5 ( Chen et al 2004). 
Another suggestion tells that HOXA5 may relate to the procaspase-2 release from the 
mitochondrion. It was found that mitochondria of different organs contain procaspase-2 and 
procaspase-9 that are released upon opening of the mitochondrial permeability transition 
pore (PTP) by different sources of activation (Susin et al 1999). In this case, it is assumed 
that HOXA5 may activate PTP opening, although bongkrekic acid (known PTP blocker) had 
no effect on apoptosis driven by HOXA5.  
In summary, HOXA5 activation leads to apoptosis induction by caspase-2 and caspase-8 
activation. Also, HOXA5 upregulation plays a significant role as a factor determining the 
balance of TNFR-pathway. Even in the presence of a small dose of TNF-α the process more 
likely ends in apoptosis if the HOXA5 gene is induced in the cell. As for numbers, quite a 
significant difference is observed when comparing the effect of concentration of TNF-α in 
different cells. Cells with inactive HOXA5 did not start the apoptosis cascade even at 100 
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ng/mL TNF-α concentration, whereas in HOXA5-induced cells 1 ng/mL of TNF-α was 
enough to activate apoptosis (Chen et al 2004). The balance mentioned above occurs since 
TNFR activation may stimulate different targets in cell metabolism. Besides caspase 
activation through FADD adapter molecules, it may also lead to activation of MAP-kinase 
(mitogen-activated pathway) and NFkB (nuclear factor kappa-light-chain-enhancer of 
activated B cells). MAP kinase activates proliferative pathways; NFkB is a protein complex 
known for being able to activate apoptosis inhibition in cells (Gupta 2002).45 So, in the 
presence of active HOXA5, the balance between the pathways is determined by supportive 
activation of caspases-2 and -8 and therefore apoptosis prevails (Chen et al 2004). 
 
Figure 3. Schematic vies of pathways described in chapter 4.2.1. TNFR is able to mediate both 
proliferative and apoptotic pathways. It was noticed that apoptotic pathway prevails in presence of 
HOXA5. The right side of the figure shows an alternative apoptotic pathway that includes the 
mitochondrion. It is hypothesized that HOXA5 might activate the opening of the PTP. Material for the 
figure is taken from Chen et al  2004. 
4.2.2. HOXA5 activation by retinoic acid. 
The expression of HOXA5 was observed to be activated by retinoic acid through different 
retinoic acid receptors. 
Retinoic acid is a vitamin A derivative that is able to activate HOX-proteins’ expression 
during embryogenesis (Chen et al 2007). It was also tested whether retinoic acid is able to 
induce HOXA5 expression as a way to activate apoptosis (Chen et al 2007). 
It was found that activated retinoic acid receptors (primarily RARα and RARβ) bind to 
specific retinoic acid responsive element (RARE) downstream from HOXA5 gene (in 3’ 
direction). This RARE contains a common RAR motif needed for binding of RAR. The 
sequence of this motif is AGGTCA which is believed to be recognized not only by RARα and 
RARβ but also by other RARs.   
It means that retinoic acid could potentially be used as chemopreventive agent; although it 
is important to mention that not all the breast cancer cell lines reacted to retinoic acid in the 
same way, so it can be used only in some specific cases. Firstly, only RARβ-positive breast 
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cancer cells may react to retinoic acid efficiently (RARβ-positive means that cell line contains 
active RARβs). Secondly, there was observed breast cancer cell line with high expression 
of RARβ but the upregulation of HOXA5 was not induced; this cell line was MDAMB435 
(Chen-Zhang et al 2007). 
4.2.3. Apoptosis induction by HXR9 activating HOXB1 – HOXB9 and connection with 
c-Fos protein. 
As discussed previously (chapter 4.1.4.), PBX is a transcriptional co-factor that may 
influence the mechanism by which HOX-proteins regulate transcription; in a form of HOX-
PBX dimer, it is able to achieve stronger DNA binding and thus more efficient activation of 
transcription (Chang et al 1995). HXR9 is a synthetic peptide containing specific amino acid 
sequence similar to that of HOX-proteins with help of which they bind to PBX co-factors. So 
HXR9 acts as an antagonist and prevents the formation of HOX-PBX dimers. 
The effect of HXR9 was tested on 78 different breast cancer cell lines and it was observed 
that its effect depends on the expression level of HOX-proteins. In the case of high 
expression of HOXB1-HOXB9 in particular cell lines, it was seen that HXR9 induces 
apoptosis, or in other words, the lack of HOX-PBX dimers induces apoptosis, possibly 
meaning that HOX proteins activate different genes or in a different way, if they act without 
interaction with PBX. In this case, the successful induction of apoptosis by HXR9 correlated 
with the c-Fos protein upregulation (Morgan et al  2012). c-Fos protein is a proto-oncogene 
and proteins coded by this gene have many different functions. It codes a protein localized 
in the nucleus that binds to Jun-family proteins to form activation protein-1 (AP-1) (Preston 
et al 1996).  These dimers function as transcription factors inducing such processes as cell 
development and growth. Moreover, these dimers are also able to induce apoptotic 
pathways, although the exact pathway is not known yet. Certain tests determined that c-Fos 
apoptosis induction is connected with p53 activation, the blocking of apoptosis was observed 
in the colorectal carcinoma (RKO) cells with the non-functional p53 gene. Moreover, 
blocking by B-cell lymphoma 2 (Bcl-2) protein was observed (Preston et al 1996).  
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Figure 4. Schematic view of the theory described in chapter 4.2.3. HXR9 acts as an antagonists and 
prevents the formation of HOX-PBX-dimers. HOX-proteins induce the expression of c-Fos in breast 
cancer. c-Fos protein induces the apoptosis. Theory for the figure is taken from Morgan-Pirard 2003, 
Morgan et al  2012. 
4.2.4. HOXB13 downregulates estrogen receptor expression in breast cancer cells. 
Tamoxifen is known as a drug for estrogen receptor-positive breast cancer cells. Its 
metabolites act as estrogen antagonists, thus decreasing estrogen effect on its target genes, 
it helps to decrease proliferation rate. 
But some patients with breast cancer still become resistant to tamoxifen treatment within the 
time due to decreased estrogen receptor expression. Correlation between tamoxifen 
resistance and HOXB13 upregulation has been observed. Therefore, this transcription factor 
was tested to have a connection with estrogen receptor expression levels. Experiments 
show that there is a HOX-binding motif in the promoter region of the estrogen receptor-α 
(ER-α) gene, so it is apparent that HOXB13 is able to affect estrogen receptor-α expression. 
So, due to decreased ER-α amount in the cell tamoxifen and its metabolites do not have a 
target to bind to (Shah et al 2013).  
4.2.5. ER-α downregulated by HOXB13, but cancer cells find an alternative way to 
stimulate proliferation. HOXB13 and interleukin-6 (IL-6). 
Although HOXB13 negatively affects ER- α expression in breast cancer cells, the latter still 
manage to continue growing. The increased amount of HOXB13 correlated with the 
increased size of the stroma in the breast cancer cell line. IL-6 expression showed the 
highest correlation with HOXB13 expression. Proliferation of stromal cells is usually more 
active during inflammation, for example, during wound healing, but interestingly it is also 
active in different carcinomas as well as in breast cancer. Therefore, it was concluded that 
cancer cells were able to activate inflammatory pathways by expressing such substances 
as cytokines (Dvorak 2015). In this case, IL-6 activates stromal growth stimulating protein 
kinase B pathway in fibroblast that surrounds breast cancer cells. Of course, this proliferative 
pathway is also activated in cancer cells and plays a role of an alternative metabolic path in 
case of inactive ER-α (Shah et al 2013).   
HOXB13 is suggested to have binding sites in the promoter of the IL-6 gene according to 
ChIP-seq analysis (Shah et al 2013). So, all these facts together may give a good 
explanation of the HOXB13 role in breast cancer cells. HOXB13 downregulates the ER-α 
gene but upregulates IL-6 gene thus activating cells' proliferative pathway. Moreover, IL-6 
plays a role in stromal growth stimulating fibroblast to act as in the inflammatory state.  
Knowing this it was tested whether inhibition of protein kinase B pathway may influence 
cancer cell growth. mTOR was chosen as a target because it relays the signal form PKB. 
Rapamycin is known to be an inhibitor of mTOR, and it was shown to cause regression of 
HOXB13-expressing breast cancer (Shah et al 2013). 
Considering the fact that HOXB13-expressing breast cancer cells still express a small 
amount of ER-α it was tested whether treatment with both tamoxifen and rapamycin would 
be more effective. This combination was significantly more effective than with tamoxifen 
alone and slightly more effective than with rapamycin alone (Shah et al 2013). Therefore, 
treatment with the rapamycin-tamoxifen combination could become a good candidate for 
ER+ breast cancer cases with high HOXB13 expression (Shah et al 2013). 
4.3. Lung cancer 
Lung cancer can be divided into two main groups: non-small-cell lung carcinoma (NSCLC) 
and small-cell lung carcinoma (SCLC). The most amount of lung cancer cases are caused 
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by NSCLC that can be divided into 3 main subclasses: adenocarcinoma, squamous cell 
carcinoma, and large-cell carcinoma. These three subclasses differ in cell morphology and 
location of cancer origin.  
4.3.1. HOX-proteins’ expression in NSCLC. 
Increased expression of HOXA5 and HOXA10 was observed in both adenocarcinoma and 
squamous-cell carcinoma. This fact seems to be self-contradictory in comparison to the role 
of these proteins in other cancer-types because HOXA5 and HOXA10 are believed to be 
antioncogenic factors according to other studies (Raman et al 2000, Bromleigh-Freedman 
2000).  
However, there are certain observations explaining this contradiction. Immunohistochemical 
staining shows that HOXA5 and HOXA10 are found mostly in the cytoplasm, but not in the 
nucleus. That is why there is a hypothesis about possible non-transcriptional action of 
HOXA5 and HOXA10, which might not have a chance to activate transcription in the 
nucleus. So, they might have interactions with other proteins and thus preventing apoptosis 
(Abe-Hamada et al 2006).  
In addition to HOXA5 and HOXA10, increased expression of HOXA1 and HOXC6 was also 
observed. Taking into account that the amount of HOXA1 correlates with increased cell 
growth in breast cancer and that HOXC6 is a possible apoptosis inhibitor in prostate cancer 
it was suggested that they could play the same role in squamous-cell carcinoma (Zhang et 
al 2003, Ramachandran et al 2005, Abe et al 2006).  
4.4. Ovarian cancer 
There are two main groups ovarian cancer is divided to: ovarian carcinoma and sex cord-
gonadal stromal tumors. The former is connected with the serous layer of cover tissues of 
ovaries, it includes, for example, high-and low-grade serous carcinoma. The second is 
associated with stromal components or germ cells themselves, for example, granulosa cell 
tumor, thecoma, and fibroma. Granulosa and theca are names of layers of ovarian follicles 
(Figure 5). 
Sex cord-gonadal stromal tumors are much rarer than ovarian carcinoma, of which high-
grade serous carcinoma is known to be the main cause of ovarian cancer (Shih et al 2004). 
 
Figure 5. Origins of ovarian cancer. It may develop from the epithelial cells, germ cells and stromal 
cells. Fibromas develop from connective tissue. Granulosa cell tumor and thecoma develop from the 
layers of ovarian follicles. Figure from Janbaz et al  2014. 
4.4.1. HOXA5 and effect on estrous cycle 
18 
 
Expression patterns of HOXA5 were tested in mice of different ages (four and ten months) 
at different phases of the estrous cycle. HOXA5 expression was observed mostly in the 
ovarian stroma in comparison to follicles, corpora lutea and ovarian stromal epithelium 
(OSE) where the expression of HOXA5 was not counted as significant. The same pattern 
was true for oviduct, where the expression of HOXA5 was more significant in the stroma. 
Reproductive cycle of mice consists of the following stages: diestrus, proestrus, estrus and 
metestrus. Growth of the follicles occurs during diestrus and proestrus. Ovulation takes 
place in estrus that is followed by metestrus involving hormonal secretion by corpora lutea. 
For 4-month old mice, there was no significant difference in HOXA5 expression between 
proestrus, estrus, and diestrus. But it was noticeably lower during the metestrus. 
Interestingly, for 10-month mice, HOXA5 expression was increased at diestrus 
(Gendronneau et al 2012). Also, expression patterns of HOXA5 were tested for the gestation 
period in mice. At the very beginning of the gestation, the expression of HOXA5 was almost 
the same as during the estrous cycle and located in the stroma. There was also observed a 
clear pattern of HOXA5 upregulation from day 6,5 to 12,5, although the difference between 
the beginning and day 12,5 was not statistically significant. However, all this data suggests 
that HOXA5 is connected with the cycle stage, age, and gestation (Gendronneau 
The comparison between inactive and active HOXA5 gene was performed. There was 
observed a significant difference in the number of estruses per month in 4,5-6 and 8-10-
month-old mice; in HOXA5-/- mice it was increased on around 1 and 2 times per month 
respectively. In age groups with a decreased number of estruses per month was also 
observed a prolonged time of diestrus and metestrus phases.   
As for hormones, 2-fold higher 17ß-estradiol concentration at estrus was measured in 10 
month-old mice, but there was no correlation between this increase and concentration of 
luteinizing hormone (Gendronneau et al 2012). 
4.4.2. HOXA5 and ovarian cyst formation 
In HOXA5-/- 10-month-old mice cyst formation was observed (Gendronneau et al 2012). The 
cyst is a rounded hollow lumen typically enclosed by epithelial cells. There are many 
different ways of cyst formation for different tissues, but here the one for ovaries will be 
described. 
EMT is a process that is generally involved in embryogenesis during the formation of several 
different tissue layers from one primordial layer. EMT is transition of apico-basally polarized 
epithelial cells into more fibroblast-like mesenchymal and migratory cell type . For example, 
the formation of mesoderm and endoderm is done with EMT during gastrulation period (Hay 
1995). Also, EMT is a way to repair tissues after different processes. In the case of ovaries, 
after ovulation, the mature ovum leaves the ovary and leaves there corporal luteum. After 
this, the formed hole in the ovarian surface epithelium (OSE) can be repaired by EMT. But 
sometimes this process may not proceed properly, and epithelium cells get entrapped in the 
stroma and are able to form cysts.  
The molecular and genetic level of this process is complicated and is mostly correlational 
with some subsequent hypotheses. Firstly, it was observed that the dominant negative form 
of transcription factor Smad-2 correlated with cyst formation in ovarian granulosa cells 
(Bristol-Gould et al 2005). Secondly, the decreased activity (heterozygote) of the GATA6 
transcription factor also correlates with the formation of cysts in ovaries (Cai et al 2009). It 
was checked whether the expression of GATA6 and Smad-2 is affected by the loss of 
HOXA5. No difference was found for GATA6 expression in HOXA5+/+ and HOXA5-/- ovaries. 
An increased amount of phosphorylated Smad-2 (its activated form) was noted in HOXA5-/- 
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mice. But it is not clear yet how exactly the loss of HOXA5 is connected with activation of 
Smad-2, because there was no difference in expression of Smad-2 ligands between control 
and HOXA5-knockout mice (Gendronneau et al 2012). 
The third regulation of EMT is EGFR (epidermal growth factor receptor) signaling, which is 
believed to control the EMT and the process of ovulation as such (Ahmed- Maines et al 
2006, Conti et al 2006). Ovulation is stimulated by the high pick of the luteinizing hormone 
that induces the transcription of amphiregulin (Areg), epiregulin (Ereg) and betacellulin (Btc) 
that are epidermal growth factors. Therefore, the expression of EGFR and its three ligands 
Areg, Ereg and Btc was analyzed. In HOXA5-/- 10-month-old mice there was observed a 
clearly decreased expression of these proteins suggesting that it may partially connect the 
loss of HOXA5 and cyst formation through diminished stimulation of EGFR signaling 
(Gendronneau et al 2012). 
4.4.3. The connection between cyst formation and ovarian cancer. 
All the above-listed examples are possible explanations of the cyst formation and its 
hypothetical dependence on the loss of HOXA5 transcription factor. But it is not enough to 
connect cyst formation and ovarian cancer. To this one more issue has to be described, and 
that is paired box gene 8 (PAX8) transcription factor. 
PAX8 is known to be active during embryogenesis when it stimulates the growth of Müllerian 
organs (ones formed by developing from the Müllerian ducts of embryo), however, in the 
mature organism this transcription factor is usually active in epithelium cells of the uterus 
and oviduct, but it is not normally expressed in ovary of the mature organism. PAX8 is used 
as a tumor biomarker for different tissues. For example, it is expressed in ovarian cysts in 
the case of ovarian cancer (Ozcan et al 2011). One of the transcription targets of PAX8 is 
Wilms tumor protein (Wt1) (Dehbi-Pelletier 1996). Expression of PAX8 and Wt1 was studied 
in different parts of ovaries on mice; it was observed that these two transcription factors 
PAX8 and Wt1 are expressed in the epithelium of the cysts inside the ovarian stroma. 
Moreover, in 4-month-old HOXA5-/- mice there were some cells observed in the ovaries 
expressing PAX8 (Gendronneau et al 2012). It was suggested that the loss of HOXA5 may 
affect the expression of many other different transcription factors including those ones 
regulating EMT and other being a master regulator of the oviduct development (PAX8). 
Altered expression disturbs estrous cycle periods' length and also is a predisposition to 
ovarian cyst formation that may play a role of the first step of cells becoming cancerous. 
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Figure 6. Schematic view of the hypothesis presented in chapter 4.4.3. Upregulation of PAX8 
correlated with decreased amount of HOXA5 in ovaries of mice. Upregulation of PAX8 and Wt1 was 
observed in ovarian cysts. It was suggested that downregulation of HOXA5 might predispose ovaries 
to development of ovarian cysts through upregulation of PAX8. Figure is based on Gendronneau et 
al 2012. 
4.4.4.  HOXA9, HOXA10, HOXA11 versus serous, endometrioid and mucinous EOCs 
respectively. 
Epithelial ovarian cancers (EOC) originates from ovarian epithelium cells. EOCs can be 
divided into three histologically different classes: serous, endometrioid and mucinous EOC. 
In the case of serous EOC, it resembles the cancer of fallopian tubes, whereas the 
endometrioid EOC is known for the formation of endometrial-like glands. And finally, 
mucinous EOC – resembles cervical and intestinal tissues. 
Fallopian tubes, uterus, and cervix arise from the müllerian ducts during the embryogenesis. 
The development of the müllerian ducts into the above-listed parts of the reproductive 
system is known to be regulated by the certain cluster of HOX-proteins called "Abdominal-
B gene" that involves three HOX-proteins: HOXA9, HOXA10, and HOXA11 (Hsieh et al 
1995, Benson et al 1996). The tissue of expression for each HOX-member of the abdominal-
B gene was analyzed in an adult rabbit to determine for which tissue type each member is 
responsible. It was found, that HOXA9 is expressed in fallopian tubes, endometrium, and 
cervix, whereas HOXA10 was mostly expressed in the mid-and posterior section of uterus 
and HOXA11 mostly in the posterior section of uterus (Figure 6) (Chen et al 2005). Also, it 
was checked whether the pattern is the same in three EOC types listed above (Figure 8). 
HOXA9 was expressed in all types of EOC, HOXA10 in endometrioid and mucinous EOC 
and HOXA11 expression was observed in mucinous EOC only (Chen et al 2005). So this 
pattern might serve an explanation of why EOCs have exceedingly similar histological 
features to the parts of the müllerian duct. Also, it demonstrates how a certain type of EOC 
might develop depending on the different expression of abdominal-B gene group. 
Also, here is one more HOX-protein that is thought to have ab effect on the EOCs. According 
to the level of differentiation, the above-listed examples of EOCs are of high-grade and 
poorly differentiated. There are also low-grade EOCs meaning that their degree of 
differentiation is higher than in high-grade carcinomas. The potential HOX-protein that 
determines whether carcinoma is low-or high-grade is HOXA7 (Chen et al 2005). The 
presence of expressed HOXA7 along with members of Abdominal-B gene group members 
showed, that HOXA7 affects the degree of the differentiation, but does not influence the 
histological type of EOCs (Figure 8). 
So, it is hypothesized that OSE cells that normally do not express HOXA9-HOXA11 proteins 
might start producing these transcription factors. It results in three different types of EOCs 
depending on what member of the Abdominal-B gene group is expressed, moreover, 
whether it will be high-or low-grade carcinoma is potentially determined by the level of 
HOXA7 expression, the presence of which increases the degree of the differentiation. 
It is not known what makes OSE repress these genes after embryogenesis as well as to 
express them in the case of EOCs. But it is known that the expression of HOXA9-HOXA11 
in the reproductive tract may be activated by progesterone or inhibited by estrogen (Benson 
et al 1998). Therefore, it is assumed that hormonal changes inside the peritoneal cavity 
(OSE faces this cavity) might change the expression of Abdominal-B gene group members 
in OSE and cause the müllerian duct-like differentiation (Chen et al 2005). 
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Figure 7. Spatially restricted HOX expression in the reproductive tract. (a) Immunohistochemical 
staining of HOXA7, HOXA9, HOXA10 and HOXA11 in normal tissues of fallopian tubes, uterus and 
vagina of the adult mouse. Scale bar, 200 µM. Anterior uterine epithelia that stained strongly for 
HOXA7, HOXA9 and HOXA10 but not for HOXA11 are indicated by arrows. (b) Staining of HOXA7 
and HOXA9 in fallopian tube, of HOXA10 in endometrium, and of HOXA11 in endocervix of the 
normal adult human. Little or no staining of HOX proteins was detected in normal human OSE. Scale 
bar, 20 µM. Figure and text from Cheng et al 2005. 
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Figure 8. Immunohistochemical staining of HOXA7, HOXA9, HOXA10 and HOXA11 in specimens 
of low-grade (SCA1) and high-grade (SCA2) serous carcinoma, low-grade endometrioid carcinoma 
(ECA1) and mucinous carcinoma (MCA1). Scale bar, 50 µM. Figure and text from Cheng et al 2005. 
4.4.5. HOXA4 – invasion promoter or suppressor? 
The increased expression of HOXA4 was observed for invasive ovarian cancer cells. But 
studies show that bigger possibility is that overexpressed HOXA4, in fact, is a way of cells 
to respond to pathological transformations of cancer cells. 
The term invasiveness is associated with such process as cell migration. This process may 
be activated by EGFR signaling through alterations in the expression of cells surface 
adhesion proteins (Katz et al 2007).  
The effect of HOXA4 expression was tested in circumstances including EGFR signaling to 
check how it influences cell migration. It was observed that the amount of EGFR increased 
in cells with siRNA against HOXA4 mRNA. In other words, along with the downregulation of 
HOXA4, the amount of EGFR has increased, also in some cells phosphorylated form of 
EGFR has increased in proportional amount to EGFR. So it might mean that expression of 
HOXA4 inhibits EGFR signaling thus preventing cell migration and lowering the probability 
to become an invasive cell (Ota et al 2009).  
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Apart from EGFR signaling, there is also another possible connection between HOXA4 and 
cell motility. HOXA4 was reported to upregulate the expression of β1-integrin (Klausen et al 
2009). This protein is a member of membrane receptors functioning in cell recognition and 
adhesion. Together with other members, it forms complexes on the cell membrane to allow 
adhesion. Therefore, the downregulation of any member would lead to fewer amount of 
complexes and could lead to worse adhesion. It was shown that knockdown of HOXA4 
actually decreases cell-cell adhesion in high-grade ovarian carcinoma cells (Klausen et al 
2009). 
So, HOXA4 may be considered to be a metastatic suppressor, the expression of which has 
a regulatory effect in response to adhesion and motility changes of cells. Its expression 
inhibits EGFR signaling and upregulates β1-integrin thus supporting cell adhesion and 
suppressing the transformation to invasive state. 
4.5. Bladder cancer 
There are three main types of bladder cancer depending on the tissue that it is developed 
from. The most common type is transitional cell carcinoma arising from transitional 
epithelium as the name implies. Transitional epithelium is a subtype of stratified epithelium 
that forms a thick layer on the inner surface of the bladder tissue. Two other types of bladder 
cancer are squamous cell carcinoma and adenocarcinoma. 
4.5.1. HOX-genes’ expression in transitional cell carcinoma. 
The discussion on associations between HOX-genes’ expression and bladder cancer cases 
will start with the overall look at HOX-genes’ up- and downregulation in all four HOX-clusters. 
The expression of all four HOX-clusters was analyzed in normal bladder tissue and bladder 
cancer tissue. Some of HOX-genes are expressed in normal bladder tissue of adult humans, 
proposing that they might be essential for differentiation or tissue homeostasis. Obviously, 
some HOX-genes get silenced in the tissue after the development.  
Although, there are many alterations in all the clusters in bladder cancer tissues, the ones 
of the C-cluster seem to be the most significant and noticeable. Part of the HOXC-cluster is 
silenced in the adult tissue of the urinary bladder, specifically HOXC4, HOXC5, HOXC6, 
HOXC9, HOXC11, and HOXC12. Four of these proteins get expressed in bladder cancer 
tissue, namely HOXC4, HOXC5, HOXC6, and HOXC11.  Here it is important to mention that 
it is not a rule working for all the cases of the bladder cancer, but rather it is true for the 
majority of bladder cancer tissue samples analyzed. But the alterations in HOXC-cluster still 
appear to function as a good marker for bladder cancer cases. 
As for HOXA-cluster, the correlations for the anterior part of the cluster are difficult to judge 
upon due to the differential expression even in the normal bladder tissue samples, 
specifically, it is true for HOXA1, HOXA2, HOXA4, and HOXA5. But the situation is different 
for the HOXA3 gene that is silent in all the samples of normal bladder tissue but gets 
upregulated in the majority of bladder cancer tissue samples. Speaking about the posterior 
region of HOXA-cluster, a relatively significant correlation is observed for the HOXA11 gene 
expression. It is active in 60 % of the normal bladder tissues and in only 6 % of the bladder 
cancer samples. But the significance of this correlation seems to be quite questionable due 
to the fact that for 2/15 pairs of samples the result of the comparison is opposite. HOXA11 
is silenced in the normal bladder tissues and activated in bladder cancer tissues (Cantile et 
al 2003). 
Correlations for the B-cluster are even less obvious than for the A-cluster. Most of the HOXB-
genes are very heterogeneously expressed in both normal and bladder cancer tissues. 
Although no correlations have been reported for the middle and posterior parts of the B-
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cluster, significant differences for the HOXB2-gene have been noted (Cantile et al 2003). It 
is inactive in 4/15 samples of normal bladder tissues, whereas it is upregulated in 11/15 
samples of bladder cancer tissues. In other words its expression is more prevalent for cancer 
tissues than for normal bladder tissues. Also, the HOXB3 expression appears to behave in 
a pattern where it is silent for all the normal bladder tissue samples, while it gets activated 
in 4/15 samples of tumor tissue (Cantile et al 2003). Still, it does not seem to be enough to 
be used as a proper prediction marker. 
And finally, the D-cluster shows the least amount of observable differences between normal 
and cancer tissue. HOXD1-D4, HOXD8-D9, and HOXD12-13 are almost always silenced in 
both normal and cancer bladder tissues with some relatively rare alterations. The clearest 
difference in expression is noticed for HOXD11 member of the D-cluster. This gene is 
observed to be inactive in all samples of normal bladder tissues, but it became active in 6/15 
samples of bladder cancer tissues (Cantile et al 2003). 
4.5.2. Cytokeratins in transitional cell carcinoma vs HOXC-cluster expression. 
In this subchapter I will discuss the interpretation of the above-listed correlative expression 
of HOX genes in various cancers. 
Cytokeratins are proteins that belong to a group of cytoskeletal components called 
intermediate filaments. They are needed to maintain the shape of the cell as well to enable 
mechanical cell-to-cell communication.  
There are many cytokeratins that are normally expressed in normal transitional epithelium, 
for example, cytokeratins 8, 18 and 19. Depending on the subtype of transitional cell 
carcinoma there were observed different patterns of expression for these (and others) 
cytokeratins (Moll et al 1988).  
Genes coding for cytokeratins 1, 3, 4, 5, 6A and 6B are located of the 12th chromosome and 
they are in physical contiguity to the 5’ end of the HOXC-cluster, whereas genes coding for 
cytokeratin 7 and basic hair Keratin 1 and 6 are physically contiguous to the 3’ end of the 
HOXC-cluster, moreover, the last two are transcriptionally regulated by HOXC13 (Jave-
Suarez et al 2002). So this data suggests that alterations in HOXC-cluster expression and 
alterations in the expression of different cytokeratins might be connected in the case of 
transitional cell carcinoma.  
4.5.3. HOXB13 in NMIBC and MIBC. 
Transition cell carcinoma is also divided into two subtypes depending on its progression: 
non-muscle invasive bladder cancer (NMBIC) and muscle-invasive bladder cancer (MBIC). 
In the case of the MBIC cancer spreads to the muscle tissue, whereas in the case of the 
NMBIC it stays in the epithelial tissues. 
Although no correlations were observed between posterior members of HOXB-cluster and 
bladder cancer (Cantile et al 2003), in another analysis it was noticed that HOXB13 may be 
a marker to distinguish between NMBIC and MBIC (Marra et al 2013). In this experiment, a 
very low expression of HOXB13 was shown for normal bladder tissue. When the tumors 
were analysed it was noticed that HOXB13 expression was significantly higher in MBIC 
when compared with NMBIC (Marra et al 2013). 
Also, the observed expression was mostly cytoplasmic, showing that HOXB13 nuclear-
cytoplasmic delocalization may correlate with the muscle invasiveness. This hypothesis is 
supported by the already observed cytoplasmic-nuclear delocalization of HOXB13 after skin 
development (Kömüves et al 2003). 
4.5.4. Hypermethylated HOXA9 as a predictive marker of NMBIC 
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Methylation of DNA regions responsible for tumor suppressors is one of the common 
features for different types of cancers. Therefore, these methylated targets may play a role 
of good predictive markers as well as be aimed in therapy.  
It was studied whether there are some DNA methylations associating with the NMBIC. 
Methylation of HOXA9, ISL1, and ALDHA3 was observed to correlate with tumor number, 
size, grade, and stage. It was suggested that HOXA9, ISL1, and ALDHA3 may play the role 
of independent markers for NMBIC cases (Marra et al 2013). 
4.6. Kidney cancer 
Kidney cancer is cancer affecting kidney cells and it is divided into two main types: renal cell 
carcinoma and transitional cell carcinoma of the renal pelvis. Renal cell carcinoma is a much 
more common type of kidney cancer; it arises from the primal tubule of the nephron. 
4.6.1. HOX-genes’ expression in renal cell carcinoma. 
The expression of all four HOX-clusters was analyzed in renal cell carcinoma to compare 
with normal kidney tissue. The most significant difference was observed in HOXD-cluster, 
namely its posterior part. HOXD9 – being active in all samples of a normal kidney of an adult 
– was active in only 4/9 samples of renal cell carcinoma. HOXD11 was observed to have 
the same activity in normal kidneys but was inactive in all samples of renal cell carcinoma 
that appears to be more even more noticeable correlation than that in case of HOXD9. 
HOXD12 seems to be active more frequently in renal cell carcinoma than in normal kidney. 
HOXA-cluster expression is almost the same for both normal kidney and renal cell 
carcinoma. But it appears that the expression of genes HOXA4-HOXA7 was slightly less 
frequent in renal cell carcinoma if one compares to a normal kidney. 
There were no strong differences in HOXB-cluster, HOXB1-HOXB5 were heterogeneously 
expressed in both normal kidney and renal cell carcinoma, whereas HOXB6-HOXB8 were 
active in samples of both groups. HOXB9 and HOXB13 were inactive in both normal and 
cancer cells. 
As for C-cluster, HOX-genes’ expression did not have any noticeable differences between 
normal and cancer samples. So the only significant alteration was observed in the posterior 
part of the HOXD-cluster, therefore HOXD9 and HOXD11 might play the role of prognostic 
markers (Cantile et al 2011). 
4.7. Melanoma. 
Melanoma is a cancer type arising from the melanocytes, pigment-producing cells of the 
bottom layer of the skin's epidermis. Nevi (more commonly called moles) may be the starting 
point of the melanoma, therefore, the amount and shape of nevi, for example, are used in 
the diagnosis of melanoma. 
4.7.1. HOXC13 and metastasis in melanoma. 
The starting point of the cancer is called the primary tumor, in case of melanoma that may 
be an abnormal mole. Eventually, cancer cells may acquire the invasive ability, so they get 
separated from the primary tumor and cause the spread of cancer to other tissues. 
The exact mechanism of this process is not understood completely. However, there was an 
association between metastasis and HOXC13 expression in melanoma. Its expression in 
nevi and primary tumors was compared to one in melanoma metastasis. The exact over-
expression was observed for this member HOXC13 in melanoma metastasis suggesting 
that its overexpression correlates with the initiation of metastasis in melanoma (Cantile et al 
2012). 
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Such integrins as very late antigens (VLA) - VLA-2, VLA-5 and VLA-6 and adhesion 
molecule ICAM-1 were observed to be highly expressed in cells with silent posterior HOXC-
genes, whereas the opposite was true for cells with actively expressed posterior HOXC-
genes (Cillo et al 1996). It suggests the above-mentioned overexpression of HOXC13 might 
cause the metastasis by affecting the expression of adhesion molecules (Cantile et al 2012). 
HOXC13 can be used as a marker and also as a therapeutic target. For example, HXR9 
(hexapeptide analog) could potentially be used to prevent interaction between HOX proteins 
and their assisting PBX proteins and thus to prevent the transcriptional function of the HOX-
protein. 
Recently, HXR9 was shown to cause apoptosis in melanoma cells. It was observed that 
HXR9 caused an increased amount of different proapoptotic factors such as Fos, for 
example. Fos could possibly be a part of activator protein (AP-1) together with JUN protein. 
AP-1 acts as transcription factor influencing cell cycle, but the exact mechanism of how it 
could cause apoptosis is not known. This data suggests that overexpressed HOX-proteins 
could act as inhibitors of proapoptotic factors, therefore, the inactivation of HOX/PBX 
interaction could cause elevated levels of proteins responsible for mediating of apoptosis 
(Morgan et al 2007).  
5. Conclusions and future perspectives. 
HOX-proteins are  transcription factors that evolve from the dispersed structure and form a 
very unique organization in vertebrates where they are split into four tight clusters on four 
different chromosomes. HOX-proteins play a fundamental role in embryogenesis controlling 
the formation of the future body plan.  
Expression of HOX-protein greatly varies among different tissues of different parts of the 
body and some of them remain active even in the adult organism, whereas some get 
silenced. The exact role of HOX-proteins in adult organisms is not clear, but there are many 
observations and correlations between their expression and different cancer types. 
Depending on the cancer type, the exact role of HOX-protein involvement is understood to 
a different extent. However, even these correlations seem to propose potential diagnostic 
and therapeutic targets for different cancer types. HOX-proteins are able to affect different 
metabolic pathways, for example, some HOX-proteins may activate apoptosis, whereas 
other are able to inactivate it. In some cases upregulation of HOX-proteins may result in 
drug-resistance, while in other cases it is more difficult to find a certain association between 
altered expression of particular HOX-protein and a certain cancer type.  
The majority of research data about HOX-proteins is made up of pure correlational analysis 
including some hypothetical interpretations. It is not possible to say conclusively whether 
HOX-proteins induce the development of certain cancer type or vice versa. The probability 
of the latter scenario appears to be slightly higher due to the observed effect of altered HOX-
protein expression serving a predominantly supportive function  
Because of the inherent complexity of cancers, the altered HOX-expression profiles cannot 
be the absolute target for cancer treatment, but further research and the unveiling of 
molecular mechanisms connected with HOX-proteins might make the picture of cancer more 
complete and reveal even more potential targets. 
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